Qiong Liu

Sorafenib plus triplet therapy with venetoclax, azacitidine and homoharringtonine for refractory/relapsed acute myeloid leukemia with FLT3‐ITD: A multicenter phase 2 study

Yu Wang, Xuejie Jiang, F. Huang, 2023, Journal of Internal Medicine.

SHP-1 inhibition targets leukaemia stem cells to restore immunosurveillance and enhance chemosensitivity by metabolic reprogramming.

X. Kang, Wenwen Zhang, Linjia Jiang, 2024, Nature cell biology.